ESC Premium Access

High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

Congress Presentation

About the speaker

Doctor Anders Nissen Bonde

Gentofte University Hospital, Gentofte (Denmark)
0 follower

8 more presentations in this session

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Speaker: Doctor T. Chao (Taipei, TW)


Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Speaker: Doctor P. Rasmussen (Copenhagen, DK)


Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Speaker: Professor J. Hartikainen (Kuopio, FI)


Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Speaker: Associate Professor S. Choi (Daegu, KR)


Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Speaker: Doctor G. Vanerio (Montevideo, UY)


Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

Speakers: Doctor A. Nissen Bonde, Doctor T. Chao, Doctor P. Rasmussen, Professor J. Hartikainen, Associate Professor S. Choi...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb